Login / Signup

Dynamic alterations of ctDNA associate with the therapeutic outcome in the advanced non-small cell lung cancer patients who received sintilimab plus anlotinib regime as 1st line therapy.

Tianqing ChuJie YuanJun LuWei NieRunbo ZhongBao-Hui HanWei ZhangChunlei ShiJialin QianYanwei ZhangXueyan ZhangJiajun TengZhiqiang GaoYuqing LouJiaqi LiHuiping QiangChao ZhangJin LiXuefeng XiaHua ZhongBaohui Han
Published in: Clinical and translational medicine (2023)
Keyphrases
  • advanced non small cell lung cancer
  • epidermal growth factor receptor
  • circulating tumor
  • cell free